The Global Endometriosis Market size is expected to reach $2.2 billion by 2028, rising at a market growth of 11.6% CAGR during the forecast period.
Endometrial-like tissue that arises in unintended places is a typical symptom of endometriosis. The tissue that develops and sheds in the uterus is known as endometrial tissue. The majority of the time, this growth occurs on and around pelvic cavity organs. Similar to the tissue inside the uterus, endometrial tissue undergoes growth, thickening, and attempts at shedding with each menstrual cycle.
The tissue can result in adhesions, tumors, and lesions that set off an inflammatory reaction since it has no way to leave the body. This may result in discomfort and other issues, such as infertility. Over the years, various causes of endometriosis have been proposed. The endometrium is the name for the lining of the uterus. According to one notion, endometrial cells can go from the uterus to the pelvic region. When a patient has a period, they pour backward along the Fallopian tubes and end up there.
Endometriosis patches have a tendency to be 'sticky' and can connect organs. Adhesions are the medical word for this. The gut or bladder, for instance, could 'stuck' to the uterus. Large endometriosis patches might develop into cysts that bleed every month during menstruation. The cysts are referred to as 'chocolate cysts' and might swell up with black blood.
Without a formal diagnosis, many endometriosis patients receive treatment based solely on their symptoms. In some instances, a laparoscopy, a straightforward surgery, is used to provide an authoritative diagnosis. In this operation, a tiny abdominal incision (often less than 1.5cm/0.6 inches) is made, through which a camera is inserted to view the pelvic cavity. Biopsies, or small tissue samples, can be taken.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Endometrial-like tissue that arises in unintended places is a typical symptom of endometriosis. The tissue that develops and sheds in the uterus is known as endometrial tissue. The majority of the time, this growth occurs on and around pelvic cavity organs. Similar to the tissue inside the uterus, endometrial tissue undergoes growth, thickening, and attempts at shedding with each menstrual cycle.
The tissue can result in adhesions, tumors, and lesions that set off an inflammatory reaction since it has no way to leave the body. This may result in discomfort and other issues, such as infertility. Over the years, various causes of endometriosis have been proposed. The endometrium is the name for the lining of the uterus. According to one notion, endometrial cells can go from the uterus to the pelvic region. When a patient has a period, they pour backward along the Fallopian tubes and end up there.
Endometriosis patches have a tendency to be 'sticky' and can connect organs. Adhesions are the medical word for this. The gut or bladder, for instance, could 'stuck' to the uterus. Large endometriosis patches might develop into cysts that bleed every month during menstruation. The cysts are referred to as 'chocolate cysts' and might swell up with black blood.
Without a formal diagnosis, many endometriosis patients receive treatment based solely on their symptoms. In some instances, a laparoscopy, a straightforward surgery, is used to provide an authoritative diagnosis. In this operation, a tiny abdominal incision (often less than 1.5cm/0.6 inches) is made, through which a camera is inserted to view the pelvic cavity. Biopsies, or small tissue samples, can be taken.
COVID-19 Impact Analysis
The COVID-19 outbreak is projected to have a negative effect on the endometriosis market due to the massive restructuring of medical schools and hospitals around the world to expand hospital capacity for COVID-19 patients. During the pandemic, the development and discovery of endometriosis treatments slowed but did not stop. Healthcare providers were only accepting emergency cases and suggested home care more to the less important cases. Moreover, the shutdown of production facilities and the lack of raw materials like gelatin significantly interrupted the supply chain for endometriosis medications.Market Growth Factors
Government efforts to raise endometriosis awareness
Establishing referral networks and care pathways with advanced imaging, pharmaceutical, surgical, fertility, and multidisciplinary interventions at tertiary and secondary centers with good connections to primary healthcare facilities. Increasing the availability of tools (such as ultrasound or magnetic resonance imaging) and medications will help health systems be better equipped to detect and treat endometriosis early (e.g., combined oral contraceptives, non-steroidal analgesics, and progestin-based contraceptives). The market growth will be boosted by numerous significant governmental entities conducting programs and other awareness programs to raise awareness. This would increasingly support the market growth during the projection period.Increasing incidence of gynecological disorders such as endometriosis
Endometriosis is a condition in which tissue that resembles the uterine lining grows outside of the uterus, resulting in pain and/or infertility. Around 10% (190 million) of women and adolescents of reproductive age suffer from endometriosis worldwide. It is a chronic condition that causes excruciating, life-altering agony during periods, sexual activity, bowel and/or bladder movements, chronic pelvic discomfort, stomach bloating, nausea, exhaustion, and occasionally depression, anxiety, and infertility.Market Restraining Factor
The absence of non-invasive endometriosis diagnostic tests
A diagnostic test's usefulness and validity are primarily determined by its sensitivity and specificity for a certain ailment. However, it can occasionally be challenging to comprehend and apply these measures to clinical decision-making. The likelihood that a positive or negative test would properly identify whether a patient has the condition is known as the positive predictive value (PPV) or negative predictive value (NPV). The endometriosis market is predicted to experience slow expansion due to the absence of appropriate and efficient diagnosis devices.Type Outlook
Based on type, the endometriosis market is segmented into superficial peritoneal lesion, endometriomas and others. The superficial peritoneal lesion segment generated the highest revenue share in the endometriosis market in 2021. This is a result of the increase in the incidence of superficial peritoneal lesions and the creation of programs to raise endometriosis awareness. Additionally, a rise in government financing for endometriosis research has accelerated the development of the superficial peritoneal lesion segment.Distribution Channel Outlook
On the basis of distribution channel, the endometriosis market is categorized into hospital pharmacy, online pharmacy, and retail pharmacy. The hospital pharmacy segment witnessed the largest revenue share in the endometriosis market in 2021. This is due to an expansion in hospital pharmacies and a rise in patients' confidence in hospitals as providers of high-quality care. The hospital pharmacy market is primarily driven by the growing trend of endometriosis therapy as an alternative to surgery. Hospital pharmacists can also help endometriosis patients, and their carers choose the right medications because they are knowledgeable about medications. Such elements all encourage sector expansion.Treatment Outlook
By treatment, the endometriosis market is bifurcated into oral contraceptives, gonadotropin-releasing hormone (GnRH) medicines and others. The gonadotropin-releasing hormone (GnRH) medicines segment recorded a prominent revenue share in the endometriosis market in 2021. They are available as a tablet, injection, shot, or nasal spray. Orilissa (elagolix), manufactured by AbbVie Inc., was the first drug given FDA approval to alleviate disease-related pain. Patients who are resistant to the first line of treatment should consider GnRH agonists and antagonists as alternatives.Regional Outlook
Region wise, the endometriosis market is analyzed across North America, Europe, Asia Pacific and LAMEA. The North America region dominated the endometriosis market with maximum revenue share in 2021. This is mostly linked to an increase in endometriosis cases, which necessitate additional treatments such as gonadotropin-releasing hormone (GnRH) medications, an increase in government financing for endometriosis research, and a considerable increase in capital income in developed countries. The sophisticated reimbursement structures that exist and are designed to lower expenditure levels also contribute to the market's expansion.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Teva Pharmaceuticals Industries Ltd., Sun Pharmaceutical Industries Ltd., Sanofi S.A., AbbVie, Inc., AstraZeneca PLC, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline PLC, Abbott Laboratories, and Consilient Health Limited.
Scope of the Study
Market Segments Covered in the Report:
By Type
- Superficial Peritoneal Lesion
- Endometriomas
- Others
By Treatment
- Oral Contraceptives
- Gonadotropin-releasing hormone (GnRH) medicines
- Others
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
By Geography
North America
- US
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Teva Pharmaceuticals Industries Ltd
- Sun Pharmaceutical Industries Ltd
- Sanofi S.A
- AbbVie, Inc
- AstraZeneca PLC
- Pfizer, Inc
- Merck & Co., Inc
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Endometriosis Market, by Type
1.4.2 Global Endometriosis Market, by Treatment
1.4.3 Global Endometriosis Market, by Distribution Channel
1.4.4 Global Endometriosis Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Endometriosis Market by Type
3.1 Global Superficial Peritoneal Lesion Market by Region
3.2 Global Endometriomas Market by Region
3.3 Global Others Market by Region
Chapter 4. Global Endometriosis Market by Treatment
4.1 Global Oral Contraceptives Market by Region
4.2 Global Gonadotropin-releasing hormone (GnRH) medicines Market by Region
4.3 Global Others Market by Region
Chapter 5. Global Endometriosis Market by Distribution Channel
5.1 Global Hospital Pharmacy Market by Region
5.2 Global Retail Pharmacy Market by Region
5.3 Global Online Pharmacy Market by Region
Chapter 6. Global Endometriosis Market by Region
6.1 North America Endometriosis Market
6.1.1 North America Endometriosis Market by Type
6.1.1.1 North America Superficial Peritoneal Lesion Market by Country
6.1.1.2 North America Endometriomas Market by Country
6.1.1.3 North America Others Market by Country
6.1.2 North America Endometriosis Market by Treatment
6.1.2.1 North America Oral Contraceptives Market by Country
6.1.2.2 North America Gonadotropin-releasing hormone (GnRH) medicines Market by Country
6.1.2.3 North America Others Market by Country
6.1.3 North America Endometriosis Market by Distribution Channel
6.1.3.1 North America Hospital Pharmacy Market by Country
6.1.3.2 North America Retail Pharmacy Market by Country
6.1.3.3 North America Online Pharmacy Market by Country
6.1.4 North America Endometriosis Market by Country
6.1.4.1 US Endometriosis Market
6.1.4.1.1 US Endometriosis Market by Type
6.1.4.1.2 US Endometriosis Market by Treatment
6.1.4.1.3 US Endometriosis Market by Distribution Channel
6.1.4.2 Canada Endometriosis Market
6.1.4.2.1 Canada Endometriosis Market by Type
6.1.4.2.2 Canada Endometriosis Market by Treatment
6.1.4.2.3 Canada Endometriosis Market by Distribution Channel
6.1.4.3 Mexico Endometriosis Market
6.1.4.3.1 Mexico Endometriosis Market by Type
6.1.4.3.2 Mexico Endometriosis Market by Treatment
6.1.4.3.3 Mexico Endometriosis Market by Distribution Channel
6.1.4.4 Rest of North America Endometriosis Market
6.1.4.4.1 Rest of North America Endometriosis Market by Type
6.1.4.4.2 Rest of North America Endometriosis Market by Treatment
6.1.4.4.3 Rest of North America Endometriosis Market by Distribution Channel
6.2 Europe Endometriosis Market
6.2.1 Europe Endometriosis Market by Type
6.2.1.1 Europe Superficial Peritoneal Lesion Market by Country
6.2.1.2 Europe Endometriomas Market by Country
6.2.1.3 Europe Others Market by Country
6.2.2 Europe Endometriosis Market by Treatment
6.2.2.1 Europe Oral Contraceptives Market by Country
6.2.2.2 Europe Gonadotropin-releasing hormone (GnRH) medicines Market by Country
6.2.2.3 Europe Others Market by Country
6.2.3 Europe Endometriosis Market by Distribution Channel
6.2.3.1 Europe Hospital Pharmacy Market by Country
6.2.3.2 Europe Retail Pharmacy Market by Country
6.2.3.3 Europe Online Pharmacy Market by Country
6.2.4 Europe Endometriosis Market by Country
6.2.4.1 Germany Endometriosis Market
6.2.4.1.1 Germany Endometriosis Market by Type
6.2.4.1.2 Germany Endometriosis Market by Treatment
6.2.4.1.3 Germany Endometriosis Market by Distribution Channel
6.2.4.2 UK Endometriosis Market
6.2.4.2.1 UK Endometriosis Market by Type
6.2.4.2.2 UK Endometriosis Market by Treatment
6.2.4.2.3 UK Endometriosis Market by Distribution Channel
6.2.4.3 France Endometriosis Market
6.2.4.3.1 France Endometriosis Market by Type
6.2.4.3.2 France Endometriosis Market by Treatment
6.2.4.3.3 France Endometriosis Market by Distribution Channel
6.2.4.4 Russia Endometriosis Market
6.2.4.4.1 Russia Endometriosis Market by Type
6.2.4.4.2 Russia Endometriosis Market by Treatment
6.2.4.4.3 Russia Endometriosis Market by Distribution Channel
6.2.4.5 Spain Endometriosis Market
6.2.4.5.1 Spain Endometriosis Market by Type
6.2.4.5.2 Spain Endometriosis Market by Treatment
6.2.4.5.3 Spain Endometriosis Market by Distribution Channel
6.2.4.6 Italy Endometriosis Market
6.2.4.6.1 Italy Endometriosis Market by Type
6.2.4.6.2 Italy Endometriosis Market by Treatment
6.2.4.6.3 Italy Endometriosis Market by Distribution Channel
6.2.4.7 Rest of Europe Endometriosis Market
6.2.4.7.1 Rest of Europe Endometriosis Market by Type
6.2.4.7.2 Rest of Europe Endometriosis Market by Treatment
6.2.4.7.3 Rest of Europe Endometriosis Market by Distribution Channel
6.3 Asia Pacific Endometriosis Market
6.3.1 Asia Pacific Endometriosis Market by Type
6.3.1.1 Asia Pacific Superficial Peritoneal Lesion Market by Country
6.3.1.2 Asia Pacific Endometriomas Market by Country
6.3.1.3 Asia Pacific Others Market by Country
6.3.2 Asia Pacific Endometriosis Market by Treatment
6.3.2.1 Asia Pacific Oral Contraceptives Market by Country
6.3.2.2 Asia Pacific Gonadotropin-releasing hormone (GnRH) medicines Market by Country
6.3.2.3 Asia Pacific Others Market by Country
6.3.3 Asia Pacific Endometriosis Market by Distribution Channel
6.3.3.1 Asia Pacific Hospital Pharmacy Market by Country
6.3.3.2 Asia Pacific Retail Pharmacy Market by Country
6.3.3.3 Asia Pacific Online Pharmacy Market by Country
6.3.4 Asia Pacific Endometriosis Market by Country
6.3.4.1 China Endometriosis Market
6.3.4.1.1 China Endometriosis Market by Type
6.3.4.1.2 China Endometriosis Market by Treatment
6.3.4.1.3 China Endometriosis Market by Distribution Channel
6.3.4.2 Japan Endometriosis Market
6.3.4.2.1 Japan Endometriosis Market by Type
6.3.4.2.2 Japan Endometriosis Market by Treatment
6.3.4.2.3 Japan Endometriosis Market by Distribution Channel
6.3.4.3 India Endometriosis Market
6.3.4.3.1 India Endometriosis Market by Type
6.3.4.3.2 India Endometriosis Market by Treatment
6.3.4.3.3 India Endometriosis Market by Distribution Channel
6.3.4.4 South Korea Endometriosis Market
6.3.4.4.1 South Korea Endometriosis Market by Type
6.3.4.4.2 South Korea Endometriosis Market by Treatment
6.3.4.4.3 South Korea Endometriosis Market by Distribution Channel
6.3.4.5 Singapore Endometriosis Market
6.3.4.5.1 Singapore Endometriosis Market by Type
6.3.4.5.2 Singapore Endometriosis Market by Treatment
6.3.4.5.3 Singapore Endometriosis Market by Distribution Channel
6.3.4.6 Malaysia Endometriosis Market
6.3.4.6.1 Malaysia Endometriosis Market by Type
6.3.4.6.2 Malaysia Endometriosis Market by Treatment
6.3.4.6.3 Malaysia Endometriosis Market by Distribution Channel
6.3.4.7 Rest of Asia Pacific Endometriosis Market
6.3.4.7.1 Rest of Asia Pacific Endometriosis Market by Type
6.3.4.7.2 Rest of Asia Pacific Endometriosis Market by Treatment
6.3.4.7.3 Rest of Asia Pacific Endometriosis Market by Distribution Channel
6.4 LAMEA Endometriosis Market
6.4.1 LAMEA Endometriosis Market by Type
6.4.1.1 LAMEA Superficial Peritoneal Lesion Market by Country
6.4.1.2 LAMEA Endometriomas Market by Country
6.4.1.3 LAMEA Others Market by Country
6.4.2 LAMEA Endometriosis Market by Treatment
6.4.2.1 LAMEA Oral Contraceptives Market by Country
6.4.2.2 LAMEA Gonadotropin-releasing hormone (GnRH) medicines Market by Country
6.4.2.3 LAMEA Others Market by Country
6.4.3 LAMEA Endometriosis Market by Distribution Channel
6.4.3.1 LAMEA Hospital Pharmacy Market by Country
6.4.3.2 LAMEA Retail Pharmacy Market by Country
6.4.3.3 LAMEA Online Pharmacy Market by Country
6.4.4 LAMEA Endometriosis Market by Country
6.4.4.1 Brazil Endometriosis Market
6.4.4.1.1 Brazil Endometriosis Market by Type
6.4.4.1.2 Brazil Endometriosis Market by Treatment
6.4.4.1.3 Brazil Endometriosis Market by Distribution Channel
6.4.4.2 Argentina Endometriosis Market
6.4.4.2.1 Argentina Endometriosis Market by Type
6.4.4.2.2 Argentina Endometriosis Market by Treatment
6.4.4.2.3 Argentina Endometriosis Market by Distribution Channel
6.4.4.3 UAE Endometriosis Market
6.4.4.3.1 UAE Endometriosis Market by Type
6.4.4.3.2 UAE Endometriosis Market by Treatment
6.4.4.3.3 UAE Endometriosis Market by Distribution Channel
6.4.4.4 Saudi Arabia Endometriosis Market
6.4.4.4.1 Saudi Arabia Endometriosis Market by Type
6.4.4.4.2 Saudi Arabia Endometriosis Market by Treatment
6.4.4.4.3 Saudi Arabia Endometriosis Market by Distribution Channel
6.4.4.5 South Africa Endometriosis Market
6.4.4.5.1 South Africa Endometriosis Market by Type
6.4.4.5.2 South Africa Endometriosis Market by Treatment
6.4.4.5.3 South Africa Endometriosis Market by Distribution Channel
6.4.4.6 Nigeria Endometriosis Market
6.4.4.6.1 Nigeria Endometriosis Market by Type
6.4.4.6.2 Nigeria Endometriosis Market by Treatment
6.4.4.6.3 Nigeria Endometriosis Market by Distribution Channel
6.4.4.7 Rest of LAMEA Endometriosis Market
6.4.4.7.1 Rest of LAMEA Endometriosis Market by Type
6.4.4.7.2 Rest of LAMEA Endometriosis Market by Treatment
6.4.4.7.3 Rest of LAMEA Endometriosis Market by Distribution Channel
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Teva Pharmaceutical Industries Ltd.
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Regional Analysis
7.2.4 Research & Development Expenses
7.2.5 Recent strategies and developments:
7.2.5.1 Product Launches and Product Expansions:
7.3 Sun Pharmaceutical Industries Ltd.
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Regional Analysis
7.3.4 Research & Development Expenses
7.4 Sanofi S.A.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expense
7.5 AbbVie, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Trials and Approvals:
7.6 AstraZeneca PLC
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Pfizer, Inc.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Regional & Segmental Analysis
7.7.4 Research & Development Expense
7.7.5 Recent strategies and developments:
7.7.5.1 Partnerships, Collaborations, and Agreements:
7.7.5.2 Trials and Approvals:
7.8 Merck & Co., Inc.
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Segmental and Regional Analysis
7.8.4 Research & Development Expenses
7.8.5 Recent strategies and developments:
7.8.5.1 Trials and Approvals:
7.9 GlaxoSmithKline PLC
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Segmental and Regional Analysis
7.9.4 Research & Development Expense
7.9.5 Recent strategies and developments:
7.9.5.1 Trials and Approvals:
7.9.5.2 Acquisition and Mergers:
7.10. Consilient Health Limited
7.10.1 Company Overview
Companies Mentioned
- Teva Pharmaceuticals Industries Ltd.
- Sun Pharmaceutical Industries Ltd.
- Sanofi S.A.
- AbbVie, Inc.
- AstraZeneca PLC
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline PLC
- Abbott Laboratories
- Consilient Health Limited
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 204 |
| Published | January 2023 |
| Forecast Period | 2021 - 2028 |
| Estimated Market Value ( USD | $ 1046.3 Million |
| Forecasted Market Value ( USD | $ 2237.8 Million |
| Compound Annual Growth Rate | 11.6% |
| Regions Covered | Global |
| No. of Companies Mentioned | 10 |
